MRC1 and colorectal carcinoma: The performance of INT2GRATE was assessed by a qualitative retrospective analysis of data obtained from 5057 patients from two clinic-based cohorts (n1 = 5018, and n2 = 39), including a total of 52 patients with LS-related CRC or EC and known pathogenic MMR variants that served as positive controls.